The city of Albuquerque supports L2B, an accelerator supporting spinouts by national laboratories and state research universities.

Imperial College London, UCL and Cambridge University have joined forces with three pharmaceutical firms to form the Apollo Therapeutics Fund.

Johnson and Johnson reinvested in Inivata, which will use the series A funding to advance its cancer diagnostics platform through clinical studies.

Jolly Pharma has backed a funding round for cancer immunotherapy developer Carsgen Therapeutics through its Jolly Innovation Ventures unit.

AstraZeneca, GSK and Johnson & Johnson have joined forces with the tech transfer offices of three universities to form the Apollo Therapeutics Fund.

Artificial intelligence-driven healthcare analytics startup iCarbonX is raising $106m for a series A round that values the company at $760m.

Brown University becomes a limited partner in Nautic Partners' latest fund that closed on its hard cap of $900m.

Juno Therapeutics increases its cancer treating T-cell research by acquiring Harvard spinout Abvitro, which focuses on diseases resistant to the immune system.